$33.58
0.77% yesterday
Nasdaq, Dec 24, 08:38 pm CET
ISIN
US90184D1000
Symbol
TWST

Twist Bioscience Corp. Target price 2025 - Analyst rating & recommendation

Twist Bioscience Corp. Classifications & Recommendation:

Buy
82%
Hold
18%

Twist Bioscience Corp. Price Target

Target Price $36.72
Price $33.58
Potential
Number of Estimates 12
12 Analysts have issued a price target Twist Bioscience Corp. 2026 . The average Twist Bioscience Corp. target price is $36.72. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 14 Analysts recommend Twist Bioscience Corp. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Twist Bioscience Corp. stock has an average upside potential 2026 of . Most analysts recommend the Twist Bioscience Corp. stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Sep '25 2026
Estimates
Revenue Million $ 376.57 433.77
20.32% 15.19%
EBITDA Margin -29.59% -8.32%
35.91% 71.88%
Net Margin -20.63% -21.50%
69.07% 4.24%

13 Analysts have issued a sales forecast Twist Bioscience Corp. 2026 . The average Twist Bioscience Corp. sales estimate is

$434m
Unlock
. This is
15.19% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$455m 20.73%
Unlock
, the lowest is
$368m 2.41%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $377m 20.32%
2026
$434m 15.19%
Unlock
2027
$499m 15.10%
Unlock
2028
$587m 17.65%
Unlock
2029
$690m 17.40%
Unlock
2030
$804m 16.54%
Unlock

12 Analysts have issued an Twist Bioscience Corp. EBITDA forecast 2026. The average Twist Bioscience Corp. EBITDA estimate is

$-36.1m
Unlock
. This is
67.59% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-8.8m 92.08%
Unlock
, the lowest is
$-86.9m 21.99%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-111m 22.88%
2026
$-36.1m 67.59%
Unlock
2027
$-6.6m 81.69%
Unlock
2028
$14.3m 315.65%
Unlock
2029
$70.0m 390.93%
Unlock
2030
$116m 65.17%
Unlock

EBITDA Margin

2025 -29.59% 35.91%
2026
-8.32% 71.88%
Unlock
2027
-1.32% 84.13%
Unlock
2028
2.43% 284.09%
Unlock
2029
10.15% 317.70%
Unlock
2030
14.38% 41.67%
Unlock

13 Twist Bioscience Corp. Analysts have issued a net profit forecast 2026. The average Twist Bioscience Corp. net profit estimate is

$-93.3m
Unlock
. This is
20.07% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-75.1m 3.28%
Unlock
, the lowest is
$-115m 47.65%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-77.7m 62.79%
2026
$-93.3m 20.07%
Unlock
2027
$-67.7m 27.40%
Unlock
2028
$-29.3m 56.71%
Unlock

Net Margin

2025 -20.63% 69.07%
2026
-21.50% 4.24%
Unlock
2027
-13.56% 36.93%
Unlock
2028
-4.99% 63.20%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Sep '25 2026
Estimates
Earnings Per Share $ -1.30 -1.54
63.89% 18.46%
P/E negative
EV/Sales 4.20

13 Analysts have issued a Twist Bioscience Corp. forecast for earnings per share. The average Twist Bioscience Corp. EPS is

$-1.54
Unlock
. This is
20.31% lower
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-1.24 3.13%
Unlock
, the lowest is
$-1.89 47.66%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-1.30 63.89%
2026
$-1.54 18.46%
Unlock
2027
$-1.12 27.27%
Unlock
2028
$-0.48 57.14%
Unlock

P/E ratio

Current -26.23 94.27%
2026
-21.83 16.79%
Unlock
2027
-30.07 37.75%
Unlock
2028
-69.45 130.96%
Unlock

Based on analysts' sales estimates for 2026, the Twist Bioscience Corp. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.84 41.05%
2026
4.20 13.27%
Unlock
2027
3.65 13.12%
Unlock
2028
3.10 15.00%
Unlock
2029
2.64 14.82%
Unlock
2030
2.27 14.19%
Unlock

P/S ratio

Current 5.45 40.03%
2026
4.73 13.19%
Unlock
2027
4.11 13.12%
Unlock
2028
3.50 15.00%
Unlock
2029
2.98 14.82%
Unlock
2030
2.56 14.19%
Unlock

Current Twist Bioscience Corp. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Barclays
Locked
Locked
Locked Dec 15 2025
Barclays
Locked
Locked
Locked Nov 17 2025
Stephens & Co.
Locked
Locked
Locked Nov 04 2025
Evercore ISI Group
Locked
Locked
Locked Oct 07 2025
Barclays
Locked
Locked
Locked Oct 02 2025
Baird
Locked
Locked
Locked May 06 2025
JP Morgan
Locked
Locked
Locked May 06 2025
Analyst Rating Date
Locked
Barclays:
Locked
Locked
Dec 15 2025
Locked
Barclays:
Locked
Locked
Nov 17 2025
Locked
Stephens & Co.:
Locked
Locked
Nov 04 2025
Locked
Evercore ISI Group:
Locked
Locked
Oct 07 2025
Locked
Barclays:
Locked
Locked
Oct 02 2025
Locked
Baird:
Locked
Locked
May 06 2025
Locked
JP Morgan:
Locked
Locked
May 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today